Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!

2022-09-14
|
Page View:

On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.

Medicilon (Hangzhou) will build as a CRO research center.  The nearly 8,000-square-meter R&D laboratory will focus on the biopharmaceuticals and AI pharmaceuticals, such as chemical drug synthesis research, compound synthesis, compound activity screening and other services.  This could accelerate the industrialization of research results.

Medicilon hangzhou.jpg

 

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

 

Medicilon Medicinal Chemistry Services

At Medicilon, Our medicinal chemistry team is capable of flexibly applying computer chemistry to assist compound design process. In the meantime, we apply advanced drug discovery technologies, including proteolysis-targeting chimera (PROTAC), DNA-encoded chemical library (DEL) and antibody drug conjugation (ADC). We are also proud of our rich experience in innovative design and patent strategies that complement our technologies. In addition, our responsive project management and effective communication help optimize our project delivery.

 

Medicilon Synthetic Chemistry Services

Medicilon is proud of our extensive expertise in synthetic organic chemistry. With a team of over 1200 chemists, our synthetic chemistry department is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate our clients' drug discovery. As we pay great attention to scientific morality, we protect our clients' intellectual property rights tirelessly and guarantee data integrity. Furthermore, our projects are always undertaken with a fundamental focus on safety and green chemistry.

 

Services

 AI supported route design and process optimization;

 Custom chemical synthesis;

 Synthesis of standards, reference compounds, and molecular probes;

 Synthesis of high-quality compounds from milligram to kilogram;

 Synthesis and resolution of chiral compounds and so on.


Innovative Drug R&D Services

AI R&D Innovation

   As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

Antibody-Drug Conjugate (ADC)

Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.

Proteolysis Targeting Chimera (PROTAC)

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.

#PROTAC #AI #drugdiscovery


Relevant newsRelevant news